JP2015536659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536659A5 JP2015536659A5 JP2015544288A JP2015544288A JP2015536659A5 JP 2015536659 A5 JP2015536659 A5 JP 2015536659A5 JP 2015544288 A JP2015544288 A JP 2015544288A JP 2015544288 A JP2015544288 A JP 2015544288A JP 2015536659 A5 JP2015536659 A5 JP 2015536659A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- disease
- pharmaceutical composition
- composition according
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 230000001404 mediated effect Effects 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 16
- 102000002689 Toll-like receptor Human genes 0.000 claims 11
- 108020000411 Toll-like receptor Proteins 0.000 claims 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 9
- 230000001363 autoimmune Effects 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000001640 Fibromyalgia Diseases 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 4
- 208000031845 Pernicious anaemia Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 4
- 201000001981 dermatomyositis Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000002491 encephalomyelitis Diseases 0.000 claims 4
- 230000009610 hypersensitivity Effects 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000000104 Arthus reaction Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000027496 Behcet disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 206010053159 Organ failure Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000033464 Reiter syndrome Diseases 0.000 claims 2
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010053879 Sepsis syndrome Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000013633 acquired hemophilia Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000001031 fetal erythroblastosis Diseases 0.000 claims 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 claims 2
- 206010051040 hyper-IgE syndrome Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000005737 orchitis Diseases 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims 1
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/085547 WO2014082254A1 (en) | 2012-11-29 | 2012-11-29 | Inhibitory oligonucleotide and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017040315A Division JP6307190B2 (ja) | 2017-03-03 | 2017-03-03 | 阻害性オリゴヌクレオチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536659A JP2015536659A (ja) | 2015-12-24 |
| JP2015536659A5 true JP2015536659A5 (enExample) | 2016-02-12 |
| JP6106280B2 JP6106280B2 (ja) | 2017-03-29 |
Family
ID=50827048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544288A Active JP6106280B2 (ja) | 2012-11-29 | 2012-11-29 | 阻害性オリゴヌクレオチド及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9688992B2 (enExample) |
| JP (1) | JP6106280B2 (enExample) |
| KR (1) | KR102027023B1 (enExample) |
| AU (1) | AU2012395641B2 (enExample) |
| CA (1) | CA2891906A1 (enExample) |
| MX (1) | MX369618B (enExample) |
| PH (1) | PH12015501182B1 (enExample) |
| RU (2) | RU2015120365A (enExample) |
| SG (1) | SG11201504142WA (enExample) |
| WO (1) | WO2014082254A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014082254A1 (en) | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
| CN108431228A (zh) * | 2015-12-25 | 2018-08-21 | Sbi生物技术有限公司 | Tlr抑制性寡核苷酸及其用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| EP3468605A4 (en) * | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
| JP7145853B2 (ja) * | 2016-11-09 | 2022-10-03 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 適応免疫調節のための方法および組成物 |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| CN112798796B (zh) * | 2021-01-04 | 2024-02-02 | 东南大学 | 一种基于dna-paint的细胞膜上pd-l1蛋白检测方法及序列 |
| WO2022170396A1 (en) * | 2021-02-12 | 2022-08-18 | ViraLok Therapeutics Pty Ltd | Agents and methods for therapy and prophylaxis |
| CN116370494A (zh) * | 2022-11-14 | 2023-07-04 | 南昌大学 | CpG寡核苷酸对糖尿病神经病理痛疾病药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072290A2 (en) | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| CN102851295B (zh) | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll 样受体调节性寡核苷酸及其用途 |
| US8030289B2 (en) | 2008-08-06 | 2011-10-04 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide and use thereof |
| CN101643496B (zh) | 2008-08-07 | 2015-09-09 | 长春华普生物技术有限公司 | 一种具有免疫抑制功能的寡核苷酸 |
| CA2762206C (en) | 2009-06-01 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| WO2014082254A1 (en) | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
-
2012
- 2012-11-29 WO PCT/CN2012/085547 patent/WO2014082254A1/en not_active Ceased
- 2012-11-29 US US14/442,799 patent/US9688992B2/en active Active
- 2012-11-29 RU RU2015120365A patent/RU2015120365A/ru not_active Application Discontinuation
- 2012-11-29 JP JP2015544288A patent/JP6106280B2/ja active Active
- 2012-11-29 SG SG11201504142WA patent/SG11201504142WA/en unknown
- 2012-11-29 AU AU2012395641A patent/AU2012395641B2/en not_active Ceased
- 2012-11-29 CA CA2891906A patent/CA2891906A1/en not_active Abandoned
- 2012-11-29 KR KR1020157014060A patent/KR102027023B1/ko not_active Expired - Fee Related
- 2012-11-29 MX MX2015006703A patent/MX369618B/es active IP Right Grant
-
2015
- 2015-05-27 PH PH12015501182A patent/PH12015501182B1/en unknown
-
2017
- 2017-05-25 US US15/605,488 patent/US10190122B2/en active Active
-
2018
- 2018-02-14 RU RU2018105485A patent/RU2018105485A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018105485A (ru) | Ингибирующие олигонуклеотиды и их применение | |
| JP2011528332A5 (enExample) | ||
| TW201202262A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| JP2024502210A5 (enExample) | ||
| JP2022526018A5 (enExample) | ||
| JP2020503010A5 (enExample) | ||
| TW202018081A (zh) | 用於B型肝炎病毒感染之RNAi藥劑 | |
| JP2016538885A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2019500873A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2016513976A5 (enExample) | ||
| JP2018520685A (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2018501299A5 (enExample) | ||
| JP2015532097A5 (enExample) | ||
| JP2017501140A5 (enExample) | ||
| JP2012508698A5 (enExample) | ||
| JP2017529398A5 (enExample) | ||
| JP2013530160A5 (enExample) | ||
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2014511897A5 (enExample) | ||
| JP2008516991A5 (enExample) | ||
| TW202200162A (zh) | 誘導外顯子５１跳讀的反義核酸 | |
| JP2010539978A5 (enExample) | ||
| CN101829117A (zh) | 吴茱萸碱在制备治疗阿尔茨海默病的药物中的应用 |